Summary:
- Visby Medical, a San Jose-based PCR diagnostics company, secured $55M in funding led by Catalio Capital Management.
- The funding will be used to launch and distribute their FDA-authorized at-home women’s sexual health test.
- Visby Medical’s technology allows for accurate infectious disease testing with PCR results in under 30 minutes.
Article:
Visby Medical, headquartered in San Jose, California, has successfully raised approximately $55 million in funding, with Catalio Capital Management leading the round. This investment will enable the company to expedite the launch and distribution of their newly FDA-approved at-home women’s sexual health test. The funding round also saw participation from existing investors such as ND Capital, Cedars Sinai Medical Center, Blue Water Life Science Advisors, Pitango Ventures, and John Doerr, demonstrating confidence in Visby Medical’s innovative approach to diagnostics.
Under the leadership of CEO Adam de la Zerda, Visby Medical is revolutionizing infectious disease testing by providing both physicians and patients with the ability to conduct accurate tests with laboratory precision. Their proprietary technology platform allows for PCR results in less than 30 minutes through single-use tests that require no specialized instruments and can fit in the palm of a hand. The company currently offers FDA-cleared tests for sexually transmitted infections (STIs) for both point-of-care settings and direct-to-consumer use at home, as well as tests for respiratory infections such as COVID-19, flu A, and flu B for point-of-care settings.
With this recent funding round, Visby Medical has now raised a total of $65 million, signifying a significant milestone in their journey to improve infectious disease diagnosis. The addition of Catalio Partner Isaac Ro to Visby Medical’s board as an observer further solidifies the company’s commitment to driving innovation in the healthcare industry. Stay tuned for more updates on Visby Medical’s groundbreaking advancements in diagnostics.
Published on FinSMEs on 19/06/2025
